COSCIENS Biopharma Inc.
Other OTCCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Peter Harry Puccetti
- Full Time Employees
- 28
- Sector
- Healthcare
- Industry
- Medical - Pharmaceuticals
- Address
- 22 Adelaide Street West Toronto ON Canada M5H 4E3
- IPO Date
- May 10, 2000
- CIK
- 0001113423
- Website
- cosciensbio.com
- Similar Companies
- Business
- COSCIENS Biopharma Inc. is a specialty biopharmaceutical company focused on the development and commercialization of a diversified portfolio of cosmeceutical, nutraceutical, and pharmaceutical products, leveraging proprietary extraction technologies to produce active ingredients from renewable plant sources; it operates through segments including Active Ingredient and Biopharmaceutical, with product offerings spanning oat beta-glucan (OBG) and avenanthramides-based formulations for cardiovascular, inflammatory, and general health applications, as well as pharmaceutical diagnostics and therapeutics such as macimorelin (Macrilen/Ghryvelin) for diagnosing adult growth hormone deficiency. The company maintains global operations across the United States, Germany, the United Kingdom, Colombia, and other international markets, with headquarters in Toronto, Canada, and a history dating to 1990 as its founding year, repositioned under its current branding after transitioning from Aeterna Zentaris Inc. It pursues growth through a merger integration with Ceapro Inc., ongoing development and prioritization of its combined product pipeline, and strategic initiatives to expand nutraceutical and cosmeceutical offerings alongside its pharmaceutical programs. Core product categories include nutraceuticals (beta-glucan-based immune support and cholesterol-lowering formulations; avenanthramide anti-inflammatory/dermatology products), cosmeceuticals (skin health and related active ingredients derived from oat beta-glucan and avenanthramides), and pharmaceutical diagnostics and therapies (macimorelin for AGHD; potential additional therapeutics under development), with commercial activities and regulatory activities spanning North America and Europe. While advancing clinical and regulatory milestones, the company emphasizes merger-driven synergies, leadership realignments, and streamlining of research and development expenditures to prioritize high-value programs in its consolidated portfolio. The latest major changes include updates on the Ceapro merger integration, management team realignment, and ongoing prioritization of the combined pipeline, alongside a continued focus on cost containment and strategic reallocation of resources to high-potential nutraceutical and cosmeceutical projects and pharmaceutical development initiatives. COSCIENS’ corporate governance and investor relations materials reflect ongoing disclosures related to merger progress, pipeline prioritization, and quarterly updates on financial performance and development milestones. For strategic context, COSCIENS operates within the life sciences sector, serving healthcare providers, pharmaceutical and nutraceutical manufacturers, dermatology and wellness customers, and diagnostic laboratories across multiple regions, with a focus on leveraging plant-derived active ingredients and a diversified product strategy to meet unmet medical and consumer health needs. [Source material and company disclosures indicate detailed product lines and strategic updates tied to the Ceapro merger and pipeline advancements, including OBG-based nutraceuticals and macimorelin-related diagnostics/pharmaceuticals.]
COSCIENS Biopharma Inc. Completes Share Capital Amendment
COSCIENS Biopharma Inc. Completes Share Capital Amendment
COSCIENS Biopharma Inc. Announces Details of Share Capital Amendment
COSCIENS Biopharma Inc. Announces Details of Share Capital Amendment
COSCIENS Biopharma Inc. Announces Results of Shareholder Meeting and Appointment of Full-Time CEO
COSCIENS Biopharma Inc. Reports Q1 2026 Results
COSCIENS Biopharma Inc. Reports Q1 2026 Results
COSCIENS Biopharma Inc. Provides Update on its Plan to Suspend U.S. Public Company Reporting Obligations
COSCIENS Comments on Unusual Market Activity
COSCIENS Biopharma Inc. Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update
COSCIENS Provides Strategic Update
COSCIENS Announces Exclusive Distribution Agreement with Wuzhou Drug International for Macrilen® in Hainan-Guangdong-Hong Kong-Macao Greater Bay Area and Singapore
Fueled by Precision and Performance, President Daniel Goldburg Leads CSCI Into Its Next Chapter as Florida's Premier Structural Shell Contractor
COSCIENS Biopharma Inc. Announces Leadership Change
COSCIENS Biopharma Inc. Reports Second Quarter 2025 Financial Results and Provides Strategic Initiatives Update
COSCIENS Biopharma Announces Results of Virtual 2025 Meeting of Shareholders
COSCIENS Biopharma Inc. Acknowledges Receipt of Intended Director Nominations from Goodwood for the Upcoming Annual and Special Meeting of Shareholders
COSCIENS Biopharma Inc. Reports First Quarter 2025 Financial Results and Provides a Corporate Update
COSCIENS Biopharma Inc. Reports Fourth Quarter and Full Year 2024 Financial Results and Provides a Corporate Update
COSCIENS Biopharma Inc. Announces Receipt of Management Cease Trade Order